KLARIA PHARMA HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.391 SEK | +30.33% |
|
+22.57% | -15.37% |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- With an enterprise value anticipated at 7.56 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.37% | 3.84M | - | ||
| +3.91% | 109B | B+ | ||
| +10.87% | 105B | B+ | ||
| +1.28% | 22.25B | B | ||
| -13.14% | 22.09B | B+ | ||
| -7.05% | 18.68B | A- | ||
| -38.36% | 17.58B | A- | ||
| -10.66% | 16.85B | B | ||
| +3.75% | 13.76B | C+ | ||
| +36.70% | 12.46B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
- Stock Market
- Equities
- KLAR Stock
- Ratings Klaria Pharma Holding AB
